Navigation Links
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Date:12/6/2008

ASH (Abstract #401, Abstract #669)

A post hoc analysis of data from the ongoing EXTEND (Eltrombopag eXTENded Dosing study) trial of refractory and non-refractory ITP patients showed that PROMACTA induced long-lasting platelet count increases and reduced clinically significant bleeding symptoms. The analysis is being presented at ASH on Monday, December 8, 2008 at 12:00 noon, PST.

In addition, data from a survey of ITP patients showed that patients are willing to accept significant risks for treatment side effects in exchange for improved efficacy and convenient administration. The survey results are being presented at ASH on Monday, December 8, 2008 at 4:30 p.m., PST.

About PROMACTA

PROMACTA is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets.

PROMACTA was discovered as a result of a research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq: LGND). It was developed by GlaxoSmithKline. GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008.

Important Safety Information

BOXED WARNING

PROMACTA may cause hepatotoxicity. Patients receiving therapy with PROMACTA must have regular monitoring of serum liver tests (see Laboratory Monitoring below). Discontinue PROMACTA if ALT levels increase to greater than or equal to 3X upper limit of normal (ULN) and are: progressive; or persistent for greater than or equal to 4 weeks, or; accompanied by increased direct bilirubin; or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation. Reinitiating treatment with PROMACTA
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. GEN Reports on the Trend Toward Predictive Toxicogenomics
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers at ... of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) ... share. Concerned SLXP investors are encouraged to contact attorney ... The investigation focuses upon the shareholder value of ... shareholders would receive only $158.00 per share in cash. ...
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... 6, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ... permanent J-code, for KRYSTEXXA® (pegloticase) became available on January ... the Centers for Medicare and Medicaid Services (CMS) and ... prescribers of KRYSTEXXA, the first and only U.S. Food ...
...  Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... with U.S.-based BioDelivery Sciences International (Nasdaq: BDSI ... is a transmucosal form of buprenorphine, a partial mu-opiate ... BEMA Buprenorphine is currently in phase III trials for ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 2Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 3Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 4Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 5Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 6Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine 2
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge youths ... towards the goal for a better future for all ... smaller groups will be held after the conference with ... Healthcare, Social and Volunteerism, Women and Youth Empowerment, to ... , Young adults aged between 18-30 years that have ...
(Date:2/28/2015)... TX (PRWEB) March 01, 2015 Heart ... estimated that 10 percent of urban adult population and ... form of heart diseases and 20-30 percent of them ... to heart ailments and coronary vascular diseases (CVD). , ... launched a new market research report titled “Indian Coronary ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to discover ... “The #1 block was lack of time and ... who created the Thinkubator Innovation Studio in Chicago. ... did not have enough time for innovative thinking and ... , Solutionman’s monthly “Accelerating Innovation Training” workshops address the ...
(Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
(Date:2/28/2015)... February 28, 2015 March—also known ... time to remind ourselves and others that suspected ... Atlantic NeuroSurgical Specialists (ANS). , Concussions are a ... for 75% of TBIs. There are 1.6-3.8 million ... sound benign, but it is a brain injury. ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
... PHILADELPHIA, Nov. 6 The American Academy of ... members of Lippincott Williams & Wilkins (LWW) nursing ... Wolters Kluwer Health, a leading provider of information ... in medicine, nursing, allied health, and pharmacy. Academy ...
... groups pay off, study finds , FRIDAY, Nov. ... starting a walking group or creating pedestrian-friendly routes ... study has found. , At a multicultural housing ... interventions meant to increase residents, walking, including sponsoring ...
... St. Michael,s Hospital working in conjunction with EMS services, paramedics ... attempts cardiopulmonary resuscitation (CPR) can quadruple the survival rate to ... research team at Rescu ( www.rescu.ca ) have found only ... help, one of the lowest rates of bystanders helping others ...
... With 125 million Americans challenged by at least one chronic illness ... chronic illnesses, early, smart estate and financial planning can make the ... its exigencies. , WHAT : ... importance for people living with chronic illness and their advisers: ...
... Bermuda, Nov. 6 Allied World Assurance,Company Holdings, ... Allied World U.S.,Nicole Baummer, Assistant Vice President for ... Professional Lines,Claims, will be speaking at this year,s ... held in Chicago, Illinois,November 11-13, 2009. , ...
... tables cleaned less often than toilet seats, study finds ... of restrooms aboard cruise ships raises the risk of ... Norovirus causes about 95 percent of acute gastroenteritis outbreaks ... norovirus outbreaks occurred on 66 ships monitored by the ...
Cached Medicine News:Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 3Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Chronic Illness: Estate Planning 2Health News:Chronic Illness: Estate Planning 3Health News:Chronic Illness: Estate Planning 4Health News:Allied World's Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference 2Health News:Allied World's Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference 3Health News:Poor Restroom Cleaning Causes Cruise-Ship Sickness 2
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... Foundation PS knee offers a femoral option and ... action that engages at 60 degrees of flexion ... and allow for 130 degrees of flexion. Femoral ... with prominent lateral flare. The constrained tibial insert ...
... BioPro Total Knee system ... anatomical replacement of all ... knee joint, while preserving ... Posterior Ligaments, bone stock, ...
Medicine Products: